Intranasal steroids: Managing allergic rhinitis and tailoring treatment to patient preference

Allergy and Asthma Proceedings

Volumn 26, Issue 6, 2005, Pages 445-451

  Meltzer, Eli O ^a  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; CORTICOSTEROID;

DRUG EFFECT; GROWTH; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INHALATIONAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PERENNIAL RHINITIS; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; GROWTH; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PATIENT SATISFACTION; PITUITARY-ADRENAL SYSTEM; RHINITIS, ALLERGIC, PERENNIAL;

EID: 30844446018     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. Allergy 49:1-34, 1994.
2. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 99: S805-S828, 1997.
3. Aberg N, Sundell J, Eriksson B, et al. Prevalence of allergic diseases in schoolchildren in relation to family history, upper respiratory infections, and residential characteristics. Allergy 51:232-237, 1996.
4. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 111:278-283, 1996.
5. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 94: 182-188, 1994.
6. Thompson AK, Juniper E, and Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85:338-347, 2000.
7. Malone D, Lawson K, Smith D, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 99:22-27, 1997.
8. Stempel DA, and Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep 2:223-230, 2002.
9. Sibbald B. Epidemiology of allergic rhinitis. In Epidemiology of Clinical Allergy. Monographs in Allergy, Vol. 31. Burr ML (Ed). Basel: Karger, 61-79, 1993.
10. Berger WE. Allergic rhinitis in children: Diagnosis and management strategies. Paediatr Drugs 6:233-250, 2004.
11. Spector S. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:S773-S780, 1997.
12. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 20:209-213, 1999.
13. Yawn BP, Yunginger JW, Wollan PC, et al. Allergic rhinitis in Rochester. Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 103:54-59, 1999.
14. Bousquet J, van Cauwenberge P, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
15. Dykewicz MS, and Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 81:463-468, 1998.
16. van Cauwenberge P, Bachert C, Passalaqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 55:116-134, 2000.
17. Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 154:771-782, 1996.
18. Barnes PJ. Molecular mechanisms of glucocorticoid action in asthma. Pulm Pharmacol Ther 10:3-19, 1997.
19. Holt PG, and Thomas JA. Steroids inhibit uptake and/or processing but not presentation of antigen by airway dendritic cells. Immunology 91:145-150, 1997.
20. Mullol J, Xaubet A, Lopez E, et al. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 50:270-274, 1995.
21. Mullol J, Lopez E, Roca-Ferrer J, et al. Effects of topical antiinflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium. Clin Exp Allergy 27:1432-1441, 1997.
22. Sim TC, Reece LM, Hilsmeier KA, et al. Secretion of chemokines and other cytokines in allergen-induced nasal responses: Inhibition by topical steroid treatment. Am J Respir Crit Care Med 152:927-933, 1995.
23. Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 316:1506-1510, 1987.
24. Scadding GK, Darby YC, and Austin CE. Effect of short-term treatment with fluticasone propionate nasal spray on the response to nasal allergen challenge. Br J Clin Pharmacol 38:447-451, 1994.
25. Wang D, Smitz J, De Waele M, et al. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count, and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 114:185-192, 1997.
26. Juniper EF, Kline PA, Hargreave FE, et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 83:627-633, 1989.
27. Darnell R, Pecoud A, and Richards DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 24:1144-1150, 1994.
28. Bunnag C, Jareoncharsri P, and Wong EC. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 47:313-317, 1992.
29. Ratner PH, Howland WC III, Arastu R et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 90:536-542, 2003.
30. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? J Allergy Clin Immunol 104:S144-S149, 1999.
31. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 129:16-23, 2003.
32. Meltzer EO, Gallet CL, Jalowayski AA, et al. Triamcinolone acetonide and fluticasone propionate aqueous nasal sprays significantly improve nasal airflow in patients with seasonal allergic rhinitis. Allergy Asthma Proc 25:53-58, 2004.
33. Gross G, Garcia J, Faruqi R, et al. Therapeutic equivalence of triamcinolone acetonide HFA and CFC nasal aerosols. Ann Allergy Asthma Immunol 94:200 (P267), 2005.
34. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 79:237-245, 1997.
35. Fokkens WJ, Cserhati E, dos Santos JM et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 89:279-284, 2002.
36. Day J, and Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 102:902-908, 1998.
37. Wang D, Duyck F, Smitz J, et al. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy 53:375-382, 1998.
38. Meltzer EO, Rickard KA, Westlund RE, et al. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol 86:286-291, 2001.
39. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 54:64-69, 1999.
40. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20:167-172, 1999.
41. Jeal W, and Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 53:257-280, 1997.
42. Howland WC III, Hampel FC Jr, Martin BG, et al. The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects. Clin Ther 18:1106-1117, 1996.
43. Wilson AM, McFarlane LC, and Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 101:470-474, 1998.
44. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 102:598-604, 1998.
45. Brannan MD, Herron JM, and Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 19:1330-1339, 1997.
46. Bachert C, Lukat KF, and Lange B. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin Exp Allergy 34:85-90, 2004.
47. Cave A, Arlett P, and Lee E. Inhaled and nasal corticosteroids: Factors affecting the risks of systemic adverse effects. Pharmacol Ther 83:153-179, 1999.
48. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:E23, 2000.
49. Schenkel E, Skoner D, Bronsky E, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Respir Med 105:1-7, 2000.
50. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 23:407-413, 2002.
51. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 90:56-62, 2003.
52. Ober S, Gentile D, Kairis E, et al. Growth velocity and HPA axis function during 1-yr treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis (AR). J Allergy Clin Immunol 115:267 (P1064), 2005.
53. Cervin A, and Andersson M. Intranasal steroids and septum perforation - an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology 36:128-132, 1998.
54. Holm AF, Fokkens WJ, Godthelp T, et al. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: A safety and biopsy study. Clin Otolaryngol 23:69-73, 1998.
55. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
56. Khanna P, and Shah A. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol 19:316-321, 2005.
57. Gerson I, Green L, and Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sens Stud 14:491-496, 1999.
58. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 131:225-231, 2004.
59. Shah SR, Miller C, Pethick N, et al. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 25:2198-2214, 2003.
60. Meltzer EO, Hadley J, Blaiss M, et al. Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. Otolaryngol Head Neck Surg 132:197-207, 2005.